Denosumab Market Report 2026

Denosumab Market Overview

• Denosumab market size has reached to $3.67 billion in 2025 • Expected to grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence • Market Trend: Accelerated Global Clinical Development Driving Wider Access To Advanced Bone Health Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Denosumab Market?

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting osteoclast formation, decreasing bone resorption, increasing bone mineral density, and reducing the risk of fracture. The main types of denosumab drug classifications include Prolia, Xgeva, and others. Prolia refers to a prescription medicine utilized to treat osteoporosis in postmenopausal women who are at high risk for fracture or cannot use another osteoporosis medication. These are available in 60 mg and 120 mg, which are used by various end-users, such as hospitals, home care, specialty clinics, and ambulatory surgical centers.

What Is The Denosumab Market Growth Forecast?

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to advancements in precision medicine and biologics, expansion of homecare and ambulatory services, increased investment in bone health research, introduction of next-generation denosumab formulations, rising demand in emerging markets. Major trends in the forecast period include increased adoption of monoclonal antibodies, expansion of osteoporosis screening programs, personalized treatment approaches for bone metastases, growth in home-based injection therapies, rising awareness of bone health in aging population.

Global Denosumab Market Segmentation

1) By Drug Classification: Prolia, Xgeva 2) By Type: 60 mg, 120 mg 3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Subsegments: 1) By Prolia: Prolia 60 Mg Injection, Prolia 1-Year Dosing Schedule, Prolia Osteoporosis Treatment 2) By Xgeva: Xgeva 120 Mg Injection, Xgeva Monthly Dosing Schedule, Xgeva Bone Metastases Management

What Are The Drivers Of The Denosumab Market?

The increasing prevalence of osteoporosis is expected to propel the growth of the denosumab market going forward. Osteoporosis is a medical condition where the bones become weak, resulting in lower bone density and a higher risk of fractures. Denosumab is used to treat osteoporosis by stopping bone resorption through the targeting of the RANK ligand. For instance, in September 2023, according to the National Center for Biotechnology Information, a US-based government agency, data from the Canadian Longitudinal Study on Aging shows that the prevalence of physician-diagnosed osteoporosis was 12.7% and DXA-confirmed osteoporosis was 5.9% in females among community-dwelling older adults. Additionally, Buttros and colleagues conducted a cross-sectional study that revealed a 24.6% prevalence of osteoporosis in postmenopausal women aged 40 to 75, diagnosed using bone mineral density (BMD) measurements. Therefore, the increasing prevalence of osteoporosis is driving the growth of the denosumab industry. The expansion of the healthcare industry is expected to propel the growth of the denosumab market going forward. The healthcare industry is the sector that provides medical services, develops treatments, and supplies products and technologies to maintain and improve human health. The healthcare industry is increasing due to the growing demand for medical services driven by aging and expanding global populations. Denosumab supports the healthcare industry by providing an effective therapy for osteoporosis and cancer-related bone loss, improving patient outcomes. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, in 2023 the number of hospitals in the US increased to 6,129 from 6,093 in 2022. Therefore, the expansion of the healthcare industry is driving the growth of the denosumab industry.

Key Players In The Global Denosumab Market

Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc

Global Denosumab Market Trends and Insights

Major companies operating in the denosumab market are focusing on expanding global clinical trials and accelerating regulatory approvals to strengthen their competitive position and broaden treatment access. Clinical trials are human-based studies that evaluate how well new drugs or therapies work and whether they are safe. For instance, in May 2023, Boan Biotech, a China-based biopharma company, initiated an international multi center Phase 3 clinical trial for its denosumab biosimilars BA6101 (Boyoubei) and BA1102, enrolling the first patient in Europe, the U.S., and Japan. These efforts follow its 2022 NMPA approval for Boyoubei in postmenopausal women at high fracture risk. By advancing global clinical development and gaining regulatory momentum, companies reinforce their competitiveness in the denosumab market.

Regional Insights

North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Denosumab Market?

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Denosumab Market Report 2026?

The denosumab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.